The islet in type 2 diabetes (T2DM) is characterized by a deficit in β-cells, increased β-cell apoptosis, and extracellular amyloid deposits derived from islet amyloid polypeptide (IAPP). In the absence of longitudinal studies, it is unknown if the low β-cell mass in T2DM precedes diabetes onset (is a risk factor for diabetes) or develops as a consequence of the disease process. Although insulin resistance is a risk factor for T2DM, most individuals who are insulin resistant do not develop diabetes. By inference, an increased β-cell workload results in T2DM in some but not all individuals. We propose that the extent of the β-cell mass that develops during childhood may underlie subsequent successful or failed adaptation to insulin resistance in later life. We propose that a low innate β-cell mass in the face of subsequent insulin resistance may expose β-cells to a burden of insulin and IAPP biosynthetic demand that exceeds the cellular capacity for protein folding and trafficking. If this threshold is crossed, intracellular toxic IAPP membrane permeant oligomers (cytidersins) may form, compromising β-cell function and inducing β-cell apoptosis. Diabetes 62:327–335, 2013

**ISLET PATHOLOGY IN TYPE 2 DIABETES**

In type 2 diabetes (T2DM), the islet is characterized by a deficit in β-cells, increased β-cell apoptosis, and extracellular amyloid deposits derived from IAPP (1,2). The question has long been posed, islet amyloid (Fig. 1) in T2DM the blood or the bullet (3,4)? In the neurosciences, the bullet hypothesis gained ascendancy under the moniker of the amyloid hypothesis in relation to Alzheimer’s disease (5). Arguably, the diabetes field was more skeptical because evidence in favor of a direct toxic effect of islet amyloid (6) was outnumbered by studies that did not identify such toxicity (7,8). However recent progress has seen a convergence of ideas by those pursuing insights into the possible link between protein misfolding and cellular degeneration in the neurosciences and the islet field. The emerging alternative but related toxic oligomer hypothesis can be summarized as follows.

Amyloid deposits occur as a consequence of misfolding and mistrafficking of proteins with the propensity to form amyloid deposits. These proteins may form a variety of oligomers, the most toxic of which are those that form relatively early and form in or interact with cellular membranes (7,9). In contrast, if misfolded IAPP oligomers organize into amyloid fibrils, these are generally less toxic but also relatively inert and as such tend to accumulate in the extracellular space where they may play a role as a physical barrier and as such contribute to cellular dysfunction (4,10). In order to appreciate why some proteins have the propensity to form oligomers and amyloid fibrils, it is helpful to consider the physical interactions that these proteins share in common.

**PROTEIN MISFOLDING AND OLIGOMERIZATION**

A common feature of amyloid proteins, including IAPP, is the ability to misfold into highly polymorphic oligomeric and fibrillar structures. In vitro experiments have shown that oligomers appear early during the misfolding process, whereas fibrils represent the end point of misfolding (11,12). Although some oligomers are likely to be on pathway to fibril formation, others are not (Fig. 2). IAPP fibrils exhibit the classical cross-β structure typical for amyloid fibrils (13), and structural models have been obtained using a number of experimental methods (14–16). Best understood structurally are IAPP fibrils with striated ribbon and twisted morphology (17), for which detailed three-dimensional structural information has been obtained (Fig. 2) (14,15). In both cases, IAPP takes up two-stranded structures. The main difference lies in how the two strands are arranged with respect to each other (Fig. 2). In the model from striated ribbon fibrils, the strands are approximately in the same plane, whereas the strands from twisted fibrils are more staggered. As is typical for almost all disease-related amyloid proteins (18), both IAPP fibril types take up a parallel and in-register structure. In these structures, the same residues from different molecules stack on top of one another. This structure is stabilized by the stacking of the same hydrophobic residues, which is much more favorable than that of residues with like charges (18). Oligomer formation is also facilitated by the interaction of hydrophobic residues, but much less is known about oligomer structures in general. This is likely due to their often transient and polymorphic nature, which makes it more difficult to study them using structural methods (19). Nevertheless, it is clear that a large range of oligomers of varying sizes and structures exist and that they share the general property of cytotoxicity (19–21). Different conformationally specific antibodies have been used to recognize different oligomer types (20,22–24). Remarkably, some of these antibodies can detect oligomers from a wider range of amyloid proteins, including IAPP. A11 is a conformationally specific antibody that recognizes a subset of toxic oligomers from a wide range of amyloid diseases (20). Although no direct structural information is available for any disease-causing amyloid oligomer, Eisenberg and colleagues (25) recently reported a major advance. They were able to determine the crystal
structure of A11-positive oligomers derived from a short αB-crystallin peptide fragment. As with amyloid oligomers in general, oligomers of this short peptide fragment were toxic. In the crystal structure, this peptide took on an overall cylindrical shape with antiparallel strands, which the authors termed cylindrin (Fig. 2). This study could provide important insights into the structure of other A11-positive oligomers.

Based on the existing structural information available for IAPP fibrils and oligomers, it is clear that IAPP is a typical amyloid protein, which likely exerts its toxicities via the same mechanisms as other amyloid proteins. This similarity also includes membrane interaction. Membranes play an important dual role in the misfolding of amyloid proteins. Membranes are not only disrupted by the toxic action of misfolded oligomers, but they can also accelerate oligomer and fibril formation by orders of magnitude (26). In the case of IAPP, it was found that this acceleration is mediated by an α-helical intermediate that forms in the presence of negatively charged lipids (27–29). A lipid that can potently activate this misfolding pathway is phosphatidyl serine, which is commonly found in the cytosolic leaflets of cellular membranes. Thus, IAPP molecules that escape the secretory pathway into the cytoplasmic space are likely to rapidly misfold and disrupt membrane integrity in vivo.
processed to its mature 37–amino acid form within the secretory pathway (Fig. 3) (33). The microenvironment of the ER favors appropriate folding and maturation of ER proteins, avoiding protein aggregation (34,35). The rate of synthesis and delivery of proinsulin and pro-IAPP into the ER is adaptively constrained to the rate at which the ER can successfully fold and export these proteins into the secretory pathway by a feedback signaling system termed the unfolded protein response (34,35). The microenvironment and chaperones in β-cell secretory vesicles are also protective against IAPP aggregation (36–43). Proteins that fail the ER quality control system are removed from the ER and degraded by endoplasmic reticulum-associated degradation (ERAD), also known as the ubiquitin/proteasome system (44). Misfolded proteins are translocated to the cytosol and ubiquitinated. Polyubiquitinated proteins are then deubiquitinated prior to passage through the proteasome (45). If misfolded proteins form aggregates, they are removed by macroautophagy (hereafter referred to as autophagy) (46,47). An isolation double membrane forms in the cytoplasm to surround such intracellular targets to generate an autophagosome that then fuses with a lysosome in which the sequestered material is degraded by hydrolytic enzymes (Fig. 3). The autophagy/lysosomal pathway is required for survival and function of β-cells and is adaptively increased under conditions of increased β-cell protein synthesis, for example in obesity (48,49). The autophagy/lysosomal pathway is particularly important for protection of long-lived cells against accumulation

**TABLE 1**

Estimated number of insulin molecules secreted per minute by a typical β-cell in a lean individual in the fasting state

|                | Insulin (mol/min) | Insulin (molecules/min) | Insulin (molecules/min/β-cell) |
|----------------|-------------------|-------------------------|--------------------------------|
|                | ~140 × 10⁻¹²      | ~84 × 10¹²               | ~10,500                        |

Given that ~30% proinsulin fails quality control, that only a relatively small amount of insulin synthesized is secreted, and that half the 24-h cycle is in the fed state, the likely synthetic rate of proinsulin per β-cell per minute is likely to be much higher in reality. The estimations take into account the following: *~6 × 10⁻²³ molecules in one mole. †~800 × 10⁶ β-cells in an adult human.

**FIG. 3.** Secretory pathway and mechanisms of β-cell defense against protein misfolding. The major β-cell secretory proteins, insulin and IAPP, are synthesized and folded in the ER and then processed within the secretory pathway (Golgi and secretory vesicles). Misfolded proteins are targeted to the ER-associated degradation, also known as ubiquitin-proteasome system (UPS), that involves ubiquitination of the targeted proteins, their deubiquitination by enzymes such as UCH-L1, and subsequent degradation by the proteasome. If the ubiquitin-proteasome system fails or if protein aggregates form, an alternative pathway of protein clearance becomes available: the autophagy pathway in which membranes surround the material to be degraded (ubiquitinated proteins and protein aggregates but also damaged organelles and aged vesicles) to form autophagosomes that fuse with lysosomes to allow degradation of their content.
of toxic amyloidogenic oligomers such as IAPP and Alzheimer’s β-protein (49–51).

Given the extraordinary workload of a typical β-cell, the high potency of human IAPP to form toxic oligomers, and the long lifespan of β-cells in humans (52), it is a remarkable tribute to the defenses against protein misfolding and aggregation that even in the setting of the further increased workload in obesity, most β-cells do not accumulate sufficient toxic oligomers to compromise β-cell function in most individuals.

DEFENSES AGAINST PROTEIN AGGREGATION OVERCOME: THE THRESHOLD CONCEPT

In humans with T2DM, the formation of intracellular oligomers and extracellular amyloid fibrils implies that the mechanisms to prevent accumulation of misfolded proteins are overcome (50). There is a threshold of IAPP expression that if exceeded leads to formation of IAPP oligomers and the adverse consequences that accrue (53–57). This threshold may be breached because the burden of protein synthesis is increased to a level that exceeds the capacity of a healthy β-cell to fold, process, and dispose of the proteins (by secretion or degradation) and/or because the threshold is decreased. Human IAPP transgenic rodent models and transduced β-cells imply that both of these contribute (53–57). Human IAPP transgenic mice and rats develop diabetes in a transgene dose-response manner (55), or if human IAPP expression is increased by drug- or obesity-induced insulin resistance (56,57).

However once the threshold for successful protein synthesis and disposal is overcome, the ubiquitin/proteasome and autophagy/lysosomal systems for elimination of protein aggregates become defective, further compromising the capacity for protecting the cell from formation of toxic IAPP oligomers (vide infra) (49,58).

THRESHOLD FOR SUCCESSFUL PROTEIN FOLDING AND DISPOSAL OVERCOME: A ROLE FOR β-CELL MASS FORMED IN CHILDHOOD?

The most common risk factor for T2DM is obesity. With increasing obesity (BMI), insulin resistance increases, requiring increased expression of insulin and IAPP (59). To appreciate the synthetic workload placed on β-cells in an individual, it is necessary to consider not only the overall insulin demand but also the number of β-cells by which this demand is met in that individual. The number of β-cells in humans increases during early childhood through the mechanism of β-cell replication and then remains relatively constant through adult life once the capacity for β-cell replication declines after early childhood (1,2,60). An underappreciated but potentially important characteristic of the period of β-cell mass expansion during the postnatal period is the wide range of β-cell mass that then accrues (Fig. 4). A wide variance in pancreatic β-cell fractional area and/or mass has been observed in adult humans, monkeys, pigs, and rodents (1,60–64). This variance is likely due in part to the intrauterine environment (65) and in part to genetic variance (vide infra) (66).

If we consider the interaction of obesity-induced insulin resistance and the wide range of β-cell mass after postnatal expansion, the increment in the protein synthetic burden per β-cell increases much more steeply in those with a low versus high number of β-cells (Fig. 5).

FIG. 4. β-Cell mass growth varies widely in childhood. Postnatal expansion of β-cell number plays a major role in establishing β-cell mass in adult humans and is highly variable between individuals. Data are from Meier et al. (60). Total number of β-cells in 46 children aged 2 weeks to 21 years. Data are represented as individual data points. Individuals with high (A, blue), intermediate (B, green), and low (C, red) β-cell numbers are shown for consideration of β-cell workload in response to obesity in Fig. 5.

THRESHOLD FOR SUCCESSFUL PROTEIN FOLDING AND DISPOSAL OVERCOME: A ROLE FOR ADOLESCENCE, PREGNANCY, AND AGING?

Transient insulin resistance and therefore increased β-cell workload occurs during adolescence in relation to high levels of growth hormone and sex steroid secretion (67) (Fig. 6). Obesity in adolescence superimposes additional insulin resistance and β-cell workload. We propose that in individuals with a low innate β-cell mass after childhood (individual C, Figs. 4 and 6), the β-cell workload may exceed the threshold for protein folding so that toxic IAPP
T2DM depends on the period of insulin resistance, and the risk for subsequent development of diabetes may occur. Moreover, if the gestational diabetes period of insulin resistance is rapidly retranscribed, the threshold for protein synthesis and folding will depend on the β-cell mass present at the end of childhood. Thus in individual A (Fig. 6), even in late life the relatively high β-cell mass that arose in childhood is sufficient. In individual B, with an intermediate β-cell mass, the capacity for β-cell protein folding is only overcome in late adult life with increasing insulin resistance. In contrast, in individual C, if he/she did not develop sustained diabetes due to obesity in adolescence or with pregnancies, diabetes onset is still likely at a young age. An implication of this model for T2DM is that if β-cell workload is maintained at relatively low levels by avoiding insulin resistance, then T2DM can be avoided in most individuals.

**LESSONS FROM GENETICS?**

 Genome-wide association studies (GWASs) have revealed a variety of T2DM susceptibility genes (e.g., *KCNJ11*, *TCF7L2*, *CDKAL1*) that are mainly involved in pancreatic β-cell maturation and function (rev. in 79). Of interest, several of these genes regulate the cell cycle and therefore may play a role in the β-cell numbers that arise during the period of postnatal expansion through β-cell replication (such as *CDKAL1* and *CDCl23* [80]). Among other identified genes, *WFS1* (encoding Wolframin) has an essential role in the ER unfolded-protein response and ER homeostasis (81) and is involved in granule acidification in β-cells (82). Any genetic alteration of *WFS1*, by its action to compromise ER function and intravesicular pH, might be expected to increase the risk of human IAPP misfolding and oligomerization. T2DM is also associated with gene variants associated with insulin-degrading enzyme. Insulin-degrading enzyme degrades IAPP and inhibits IAPP aggregation and toxicity in vitro (83). A rare missense mutation, S20G, that leads to increased propensity of IAPP to form oligomers is associated with T2DM, providing a proof of principal of the potential importance of IAPP in the pathogenesis of diabetes (84,85).

Although insulin resistance is a well-known risk factor for T2DM (86), GWASs have uncovered relatively few

![Risk for T2DM](image_url)
associations with T2DM attributable to insulin-signaling pathways. However the current model links insulin resistance from any cause to T2DM risk through formation of inadequate \( \beta \)-cell number in childhood and/or a reduced capacity for protein folding, and both these mechanisms are prominent in the GWASs to date.

**WHERE DO OLIGOMERS FORM, AND HOW DO THEY DAMAGE CELLS?**

Amyloidogenic proteins such as IAPP appear to induce cytotoxicity by disrupting cellular membrane integrity in the form of small nonfibrillar oligomers (7). Toxic IAPP oligomers form within the secretory pathway but are then found liberated from this compartment adjacent to disrupted vesicle membranes (Fig. 1C) (50). Moreover, membranes of mitochondria adjacent to these cytosolic IAPP toxic oligomers are disrupted, implying that \( \beta \)-cell function as well as viability is likely compromised by toxic IAPP oligomers (Fig. 1). This is supported by the decline in \( \beta \)-cell function that precedes loss of \( \beta \)-cell mass in the human IAPP transgenic rat model of T2DM (64).

It is unclear where the toxic oligomers form within the secretory pathway and even to what extent pro-IAPP has been processed before these oligomers form. Since toxic oligomers of amyloidogenic proteins form on an alternative pathway to the majority of amyloid fibrils, just because IAPP-derived amyloid is primarily composed of the \( \beta \)-amyloid amino acid form of IAPP does not mean that the toxic oligomers are. A case has been made that these toxic oligomers might be composed of pro-IAPP (87). Pro-IAPP oligomers could form in the ER and/or Golgi, whereas IAPP oligomers would form in insulin secretory vesicles where pro-IAPP processing to IAPP is completed.

Toxic oligomers associated with ER membranes (50) may contribute to ER stress in \( \beta \)-cells of individuals with T2DM (88). Human IAPP transgenic rodent models of T2DM that form toxic IAPP oligomers have ER stress–induced apoptosis (88,89). In those models, toxic oligomers are found in association with the ER membrane, which is likely the cause of unregulated ER \( \text{Ca}^{2+} \) release to the cytosol and consequent hyperactivation of the \( \text{Ca}^{2+} \)-sensitive protease calpain-2 (53). The presence of this deleterious mechanism in humans was supported by the detection of the cleaved form of \( \alpha \)-spectrin, a marker of calpain hyperactivation, in \( \beta \)-cells of individuals with T2DM (53).

Once IAPP toxic oligomers are formed, they disrupt the pathways of protein clearance and likely thereby lead to further accumulation of protein aggregates. The ubiquitin/proteasome system is dysfunctional in \( \beta \)-cells of human individuals with T2DM, as demonstrated by the accumulation of polyubiquitinated proteins (58). Increased expression of oligomerization-prone human IAPP leads to an accumulation of polyubiquitinated proteins mediated by a deficit in the deubiquitinating enzyme ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (58). UCH-L1 downregulation enhances ER stress–induced \( \beta \)-cell apoptosis, and UCH-L1 deficiency was observed in \( \beta \)-cells of individuals with T2DM (58). Therefore, defective protein degradation in \( \beta \)-cells in T2DM can, at least in part, be attributed to misfolded human IAPP leading to UCH-L1 deficiency, which in turn further compromises \( \beta \)-cell viability by exacerbating ER stress.

In summary, once the threshold for successful synthesis, folding, processing, and secretion of IAPP is breached and intracellular toxic oligomers begin to form, unless this is rapidly reversed, a cascade of events occurs that further compromises \( \beta \)-cell function and increases vulnerability to \( \beta \)-cell apoptosis (Fig. 7). Moreover, the resulting declining \( \beta \)-cell number adds an increased synthetic burden on the remaining \( \beta \)-cells exacerbating the accumulation of toxic oligomers.

**EXTRACELLULAR ISLET AMYLOID AS A DIFFUSION BARRIER?**

Although accumulating data suggest that toxic IAPP oligomers form intracellularly (50,55,90), and on a separate pathway to the majority of fibrils present extracellularly (25), this does not rule out a contributory role of extracellular islet amyloid in \( \beta \)-cell dysfunction. It is not known why extracellular islet amyloid forms in most islets in T2DM and occasional islets in nondiabetic individuals. The most obvious explanation is that it represents the debris from cell apoptosis trapped on the vascular endothelium where it appears to accumulate. Support for this is provided by the absence of extracellular islet amyloid in vivo models of relatively rapid \( \beta \)-cell loss with high human IAPP expression (55) but accumulation of extracellular islet amyloid in more gradual-onset in vivo models (57,64).

However, islet amyloid develops rapidly in islets derived from a human IAPP transgenic mouse in vitro. Also in this model, it was reported that there was no evidence of ER stress and that toxicity was attributed to extracellular islet amyloid (91). It is difficult to interpret studies of \( \beta \)-cell apoptosis in isolated islets in which there is already a markedly increased frequency of \( \beta \)-cell apoptosis due to anoxia and nutritional deprivation of the majority of cells. In vivo, each \( \beta \)-cell is directly supplied by oxygen and nutrients via an afferent vascular capillary loop, whereas in isolated islets only cells at the out rim of the sphere of ~3,000 cells have direct nutrient and oxygen supply, the remainder requiring diffusion through the sphere of cells given the loss of a vascular supply. It is also therefore perhaps not surprising that there is rapid accumulation of extracellular IAPP–derived islet amyloid in vitro because there is no means to export the secreted IAPP or IAPP debris from apoptotic cells that accumulates between cells. This rapidly accumulating amyloid between cells in vitro presumably also acts as a diffusion barrier and, as such, may contribute to \( \beta \)-cell apoptosis in islets in vitro.

The question arises, does the extracellular islet amyloid in vivo contribute to \( \beta \)-cell dysfunction or apoptosis in T2DM in the vascularized islet? We have found no relationship between islet amyloid and \( \beta \)-cell apoptosis in humans with T2DM (1) or transgenic human IAPP rodent models (8). On the other hand, Jurgens et al. (92) report an increase in a derivative of \( \beta \)-cell apoptosis (\( \beta \)-cell apoptosis/insulin-positive area/islet area) related to a score of islet amyloid in humans with T2DM and nondiabetic individuals in the same analysis. A more compelling case for an adverse effect of extracellular islet amyloid can perhaps be made for transplanted human islets. Extracellular islet amyloid also develops rapidly in transplanted human islets (93), a circumstance that more closely mirrors islets in vitro, since transplanted islets take several days to reestablish a vascular supply (94). During that period there is rapid loss of \( \beta \)-cells, presumably in part because of anoxia and nutrient deprivation but perhaps exacerbated by the diffusion barrier of extracellular islet amyloid. A case can also be made that the...
extracellular islet amyloid might compromise cell to cell communication, known to be important for islet function. It is unknown at present to what extent this might be relevant in vivo.

CONCLUSION

Cross-sectional autopsy studies reveal a β-cell deficit and increased β-cell apoptosis in T2DM. Though an increased β-cell workload (insulin resistance) is a risk factor for T2DM, most individuals adaptively increase insulin and IAPP expression and secretion without β-cell failure. Experimental evidence supports the concept of a threshold of synthetic burden in β-cells expressing amyloidogenic human IAPP beyond which accumulation of misfolded toxic oligomers comprises β-cell function and viability. We propose that the wide range of β-cell numbers between individuals that becomes apparent after the period of postnatal β-cell mass expansion may serve as an important predictor of risk for T2DM. In those individuals with a relatively low compliment of β-cells, insulin resistance would markedly increase the already high burden for IAPP and insulin folding and disposal (secretion or degradation) per β-cell, potentially exceeding the threshold in at least some β-cells. In those β-cells, the accumulating toxic oligomers would compromise β-cell function and viability, leading to a progressive loss of β-cell function and number. As β-cell function declines in the presence of insulin resistance, hyperglycemia that develops can initially be reversed by an increase in insulin sensitivity (for example, delivery of child after gestational diabetes mellitus or introduction of an exercise regimen [95]) but eventually becomes irreversible if sufficient β-cell mass is lost. We thus postulate that the innate β-cell mass that arises according to intrauterine development and genetic imprinting may be an important predictor of risk for T2DM in the setting of insulin resistance. To rigorously test this postulate it would be necessary to measure β-cell mass in vivo in prospective studies of young adults over many years.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK059579, DK061539, DK077967) and the Larry L. Hillblom Foundation to P.C.B., and the National Institutes of Health (AG027936) to R.L.

No potential conflicts of interest relevant to this article were reported.

S.C., R.L., T.G., A.V.M., and P.C.B. researched the data and wrote, reviewed, and edited the manuscript.
REFERENCES

1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102–110

2. Rahier J, Guiot Y, Goebels RM, Sempoux C, Hencquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4):S2–42

3. Klöppel G, Lühr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Diabetol Res 1985;4:110–125

4. Clark A, Cooper GJ, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987;2:231–234

5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356

6. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756–760

7. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999;48:491–498

8. Butcher AE, Janson J, Busungu WC, Butler PC, Langen R. Structure of beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003;52:2304–2314

9. McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 1996;271:26482–26489

10. Hayden MR, Karuparthi PR, Manrique CM, Lastra G, Habibi J, Sowers JR. Isoform-specific down-regulation of the interleukin-2 receptor by an islet amyloid polypeptide-related toxic amyloid particle. Biochem J 2003;374:113–121

11. Caughey B, Lansbury PT. Protoamyloid fibrils: molecular insights from electron para-diffraction. FEBS J 2010;277:4602–4613

12. stiltofouliou M, Jayasinghe SA, Langen R. Structure of alpha-helical fibrils containing aggregates by human amylin: a potential role for defective DnaJ and GRP78/BiP suppression of misfolding and formation of beta-sheet containing aggregates by human amylin: a potential role for defective chaperone biology in Type 2 diabetes. Biochem 2010;49:10918–10925

13. Wiltzius JJ, Sievers SA, Sawaya MR, et al. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Sci 2008;17:1467–1474

14. Jayasinghe SA, Langen R. Membrane interaction of islet amyloid polypeptide. Biochim Biophys Acta 2007;1768:2002–2009

15. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012;81:707–703

16. Volchuk A, Ron D. The endoplasmic reticulum stress response in the pancreatic beta-cell. Diabetes Obes Metab 2010;12(Suppl. 2):S47–S57

17. Breder CJ, Hartman K, Nanga RP, et al. Role of zinc in human islet amyloid polypeptide aggregation. J Am Chem Soc 2010;132:8073–8083

18. Breder CJ, Salamendi S, Banavwoothy A. Membrane disruption and early amyloid formation in the diabetes-related toxic amyloid peptide IAPP from a molecular perspective. Acc Chem Res 2012;45:454–462

19. Charge SB, de Koning EJ, Clark A. Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Biochemistry 1995;34:14588–14593

20. Khentimourian L, Domènech E, Doux JP, Koorangevel MC, Killian JA. Low pH acts as inhibitor of membrane damage induced by human islet amyloid polypeptide. J Am Chem Soc 2011;133:15508–15504

21. Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A. Processing of pro-islet amyloid polypeptide (proAβP) by the prohormone convertase family. FEBS Lett 1996;378:227–231

22. Stefani M. Biochemical and biophysical features of both oligomer/trimeric and amyloid fibril islet amyloid polypeptide. Diabetes 2003;52:102–110

23. Suylen DP, et al. Impaired processing of human pro-islet amyloid polypeptide is not a causative factor for fibril formation or membrane damage in vitro. Biochemistry 2008;47:10918–10925

24. Kudva YC, Mueske C, Butler PC, Eberhardt NL. A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. J Biol Chem 1998;273:801–808

25. Hickey AJ, Bradley JW, Skea GL, et al. Proteins associated with immunopurified granules from a model pancreatic islet beta-cell system: proteomic snapshot of an endocrine secretory granule. J Proteome Res 2009;8:178–186

26. Chien Y, Atken JF, Zhang S, et al. The chaperone proteins HSP70, HSP40/ DnaJ and GRP78/BiP suppress misfolding and formation of beta-sheet-containing aggregates by human amylin: a potential role for defective chaperone biology in Type 2 diabetes. Biochem 2010;432:113–121

27. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation. Cell 2008;134:259–267

28. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective lysosomal pathway in pancreatic beta-cells: protective role of p62-positive autophagosomes. Mol Cell 2009;34:459–467

29. Higham DJ, Uchiyama M, et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab 2008;8:325–328

30. Rivera JF, Jurge T, Daval M, et al. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic beta-cells: protective role of p66-positive cytoplasmic inclusions. Cell Death Differ 2011;18:415–426

31. Gurlo T, Ryazantsev S, Huang CJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 2010;176:861–869

32. Dikalova RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007;120:491–498

33. Cnop M, Hughes SJ, Igoillo-Esteve M, et al. High-fat diet impairs lysosomal enzyme activity and increases beta-cell apoptosis in humans with type 2 diabetes. J Lipid Res 2003;44:1213–1219

34. Jayasinghe SA, Langen R. Lysosomal membranes modulate the structure of islet amyloid polypeptide. Biochemistry 2005;44:1213–1219

35. Kwon Y, Goebels RM, Sempoux C, et al. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 1996;271:26482–26489

36. Wiltzius JJ, Sievers SA, Sawaya MR, et al. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Sci 2008;17:1467–1474

37. Golabkous CB, Cooper GJ, Golde KN, et al. Polymeric fibrillar assembly of human amylin. J Struct Biol 1997;110:17–27

38. Margittai M, Langen R. Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Q Rev Biophys 2008;41:265–297

39. Bemporad F, Chiti F. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-ductility relationships. Chem Biol 2012;19:315–327

40. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2005;280:29683–29683

41. Stefan M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J 2010;277:4002–4013

42. Lacor PN, Bnieli MC, Chang L, et al. Synthetic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 2004;24:1091–1100

43. Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23–35

44. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486–489

45. Laganowsky A, Liu C, Sawaya MR, et al. Atomic view of a toxic amyloid small oligomer. Science 2012;335:1228–1231
54. Matveyenko AV, Butler PC. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J 2006;47:225–233
55. Janson J, Soeller WC, Roche PC, et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 1990;87:7283–7288
56. Couce M, Kane LA, O’Brien TD, et al. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 1996;45:1094–1101
57. Soeller WC, Janson J, Hart SE, et al. Islet amyloid-associated diabetes in rodents as models for type 2 diabetes. ILAR J 2006;47:225–238
58. Mulder H, Abrin B, Stridsberg M, Sundler F. Non-parallellism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment. Diabetologia 1995;38:395–402
59. Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008;57:1584–1594
60. Ritze RA, Butler AE, Rizza RA, Yeldhuis JD, Butler PC. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 2006;29:717–718
61. Kjems LL, Kirby BM, Welsh EM, et al. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 2001;50:2001–2012
62. Saisho Y, Butler AE, Manessos E, et al. Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys. Diabetologia 2010;53:111–114
63. Matveyenko AV, Butler PC. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (Hipp) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 2006;55:2106–2114
64. Matveyenko AV, Singh I, Shin BC, Georgiea S, Devaskar SU. Differential effects of prenatal and postnatal nutritional environment on beta-cell mass development and turnover in male and female rats. Endocrinology 2010;151:5647–5656
65. Yaghoobtari H, Freathy RM. Genetic origins of low birth weight. Curr Opin Clin Nutr Metab Care 2012;15:258–264
66. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Autophagy and aging: the importance of maintaining quality control. Ageing Res Rev 2010;9:501–511
67. Berger B, Stenström G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care 1999;22:777–778
68. Basu R, Beeda E, Obere AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003;52:1738–1748
69. Weber TA, Reichert AS. Impaired quality control of mitochondria: aging from a new perspective. Exp Gerontol 2010;45:503–511
70. Koga H, Kaushik S, Cuervo AM. Protein homeostasis and aging: The importance of exquisite quality control. Ageing Res Rev 2011;10:205–215
71. Wang XF, Li S, Choi AP, Bronstein JM. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol Dis 2006;23:198–205
72. Cuervo AM, Bergamini E, Brunk UT, Droge W, Ffrench M, Termine A. Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 2005;1:131–140
73. Termine A. The effect of age on formation and elimination of autophagic vacuoles in mouse hepatocytes. Gerontology 1995;41(Suppl. 2):319–326
74. Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 2005;1:590–599
75. Mawuenyega KG, Sigurdson W, Ovov V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010;330:1774
76. Masini M, Bugiani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 2005;52:1083–1086
77. Bonnefond A, Floguel P, Vaxillaire M. The emerging genetics of type 2 diabetes. Trends Mol Med 2010;16:407–416
78. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638–645
79. Fonseca SG, Ishigaki S, Osolowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 2010;120:744–755
80. Hatanaka M, Tanabe K, Yanai A, et al. Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 2011;20:1274–1284
81. Bennett RG, Hamel FG, Duckworth WC. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in INS1 cell cultures. Diabetes 2003;52:2315–2320
82. Seino S; Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Diabetologia 2001;44:906–909
83. Ma Z, Westerman GT, Sakagashira S, et al. Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 2001;8:242–249
84. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 1990;39:283–288
85. Marzban L, Rhodes CJ, Steiner DF, Haataja L, Halban PA, Verchere CB. Impaired NHE2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes 2006;55:2192–2201
86. Huang CJ, Lin CY, Haataja L, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007;56:2016–2027
87. Huang CJ, Haataja L, Gurlt T, et al. Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2007;293:E1656–E1662
88. Hiddinga HJ, Eberhardt NL. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am J Pathol 1999;154:1077–1088
89. Hull RL, Zaiak S, Udayasankar J, Astrum-Mourney K, Subramanian SL, Kahn SE. Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 2009;52:1102–1111
90. Jurgens CA, Toukatly MN, Fligner CL, et al. Enhanced in vitro production of human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2007;293:E1656–E1662
91. Hull RL, Zaiak S, Udayasankar J, Astrum-Mourney K, Subramanian SL, Kahn SE. Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 2009;52:1102–1111
92. Jurgens CA, Toukatly MN, Fligner CL, et al. Enhanced in vitro production of human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2007;293:E1656–E1662
93. Westermark P, Elizak DL, Pipeleers DG, Hellersrom C, Andersson A. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 1995;38:543–549
94. Griffith RC, Scharp DW, Hartman BK, Ballinger WF, Lacy PE. A morphologic study of intrahepatic portal-vein islet isografts. Diabetes 1977;26:201–214
95. Tuomilehto J, Lindstrom J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350